BMY Shares Rise 1.09% as Trading Volume Ranks 281st Amid Oncology Pipeline Progress and European Biotech Partnership

On September 9, 2025, Bristol-Myers Squibb (BMY) closed with a 1.09% increase, trading at a volume of $370 million, which ranked it 281st in terms of trading activity among listed stocks. The move followed a strategic update from the company highlighting progress in its oncology pipeline, including positive Phase III trial data for a novel immunotherapy candidate. Analysts noted the development could accelerate regulatory timelines for key products in the next fiscal year.

Recent corporate disclosures indicated a restructured collaboration with a European biotech firm, expanding Bristol’s access to preclinical assets in rare disease therapeutics. While the partnership does not directly impact near-term revenue, it strengthens long-term R&D positioning. Market participants interpreted the news as a signal of management’s commitment to innovation, though near-term guidance remained unchanged.

To run this back-test for you I need a few extra details so I can set the data pull and calculations up correctly: 1. Universe • Should we consider all U.S. listed common stocks, or a narrower set (e.g., only S&P 500 constituents, only NYSE/Nasdaq, etc.)? 2. Buy/Sell timing • Do you want to buy at today’s close and exit at tomorrow’s close (close-to-close), or buy at tomorrow’s open and exit at tomorrow’s close (open-to-close)? 3. Weighting • Equal-weight across the 500 names each day (standard approach)? 4. Transaction costs & slippage • Should we ignore them, or apply a default round-trip cost (e.g., 5 bp in and 5 bp out)? Once I have these points I can generate the retrieval plan and run the back-test.